About: Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.49 (-6.81%)
IMRX NASDAQ Immuneering Corp
Immuneering Corp share price
IMRX price activity
Last Price
$3.490
Change (24hr)
-0.26 USD (6.81%)
Volume
795.58K
Volume (4w avg)
-
Open
$3.76
Day Range
$3.45 - $3.94
Previous Close
$3.75
Last Trade
02 Nov, 9:00 pm GMT+0
Delayed
02 Nov, 9:00 pm GMT+0
IMRX price performance
Delayed
02 Nov, 9:00 pm GMT+0
IMRX details
IMRX Market Signals